Literature DB >> 30055186

The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer.

Lutske Lodewijk1, Stefan M Willems2, Koen M A Dreijerink3, Bart de Keizer4, Paul J van Diest2, Abbey Schepers5, Hans Morreau6, Han J Bonenkamp7, Ilse A C H Van Engen-van Grunsven8, Schelto Kruijff9, Bettien M van Hemel10, Thera P Links11, Els Nieveen van Dijkum12, Susanne van Eeden13, Gerlof D Valk3, Inne H M Borel Rinkes1, Menno R Vriens14.   

Abstract

Entities:  

Keywords:  Imaging; Immunohistochemistry; Medullary thyroid cancer; Prostate-specific membrane antigen; Theranostics; Tissue microarray

Mesh：

Substances：

Year:  2018        PMID： 30055186     DOI： 10.1016/j.humpath.2018.06.035

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


× No keyword cloud information.
  5 in total

1.  Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center.

Authors:  Marceline W Piek; Lisa H de Vries; Maarten L Donswijk; Bart de Keizer; Jan Paul de Boer; Lutske Lodewijk; Rachel S van Leeuwaarde; Menno R Vriens; Koen J Hartemink; Iris M C van der Ploeg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-15       Impact factor: 10.057

2.  Discovering pathways in benign prostate hyperplasia: A functional genomics pilot study.

Authors:  Zheling Chen; Minyao Ge
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

Review 3.  Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.

Authors:  Heying Duan; Andrei Iagaru; Carina Mari Aparici
Journal:  Nanotheranostics       Date:  2022-01-01

4.  68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617.

Authors:  Lisa H de Vries; Lutske Lodewijk; Arthur J A T Braat; Gerard C Krijger; Gerlof D Valk; Marnix G E H Lam; Inne H M Borel Rinkes; Menno R Vriens; Bart de Keizer
Journal:  EJNMMI Res       Date:  2020-03-06       Impact factor: 3.138

Review 5.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.